Boston Scientific Corporation (BSX) : Aureus Asset Management scooped up 43,281 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 674,356 shares of Boston Scientific Corporation which is valued at $15.1 Million.Boston Scientific Corporation makes up approximately 3.38% of Aureus Asset Management’s portfolio.
Other Hedge Funds, Including , Ikos Cif Ltd sold out all of its stake in BSX during the most recent quarter. The investment firm sold 7,600 shares of BSX which is valued $169,860.Diamond Hill Capital Management Inc boosted its stake in BSX in the latest quarter, The investment management firm added 739,511 additional shares and now holds a total of 20,339,317 shares of Boston Scientific Corporation which is valued at $454.6 Million. Boston Scientific Corporation makes up approx 2.92% of Diamond Hill Capital Management Inc’s portfolio.Gamco Investors Et Al reduced its stake in BSX by selling 25,700 shares or 3.13% in the most recent quarter. The Hedge Fund company now holds 796,046 shares of BSX which is valued at $17.5 Million. Boston Scientific Corporation makes up approx 0.12% of Gamco Investors Et Al’s portfolio.Wedge Capital Management L L Pnc boosted its stake in BSX in the latest quarter, The investment management firm added 88,099 additional shares and now holds a total of 2,270,799 shares of Boston Scientific Corporation which is valued at $50 Million. Boston Scientific Corporation makes up approx 0.52% of Wedge Capital Management L L Pnc’s portfolio.
Boston Scientific Corporation closed down -0.14 points or -0.62% at $22.39 with 86,38,193 shares getting traded on Wednesday. Post opening the session at $22.54, the shares hit an intraday low of $22.32 and an intraday high of $22.62 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.